Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
111 hedge funds and large institutions have $306M invested in Generation Bio in 2022 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 24 reducing their positions, and 8 closing their positions.
250% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 8
79% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 24
22% more funds holding
Funds holding: 91 → 111 (+20)
0.08% more ownership
Funds ownership: 9.7% → 9.78% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $364M → $306M (-$57.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.16M |
| 2 |
Goldman Sachs
New York
|
+$3.77M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.66M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.26M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$10M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.61M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$7.47M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.49M |
| 5 |
JP Morgan Chase
New York
|
-$1.16M |
GBIO Hedge Fund Activity: Q3 2022 in Review
111 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2022, worth a combined $306M — down 16% from $364M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GBIO positions and 8 closed out — a net gain of 20 holders — while 43 added to existing stakes and 24 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $5.16M. The largest seller was Yiheng Capital Management, cutting an estimated $10M.
- 111 institutional investors held Generation Bio (GBIO) as of Q3 2022, up from 91 in Q2 2022.
- Funds reported $306M of Generation Bio stock for Q3 2022, down 16% quarter-over-quarter.
- 28 funds opened new Generation Bio positions in Q3 2022 and 8 closed out, a net change of +20 holders.
- The largest Generation Bio buyer in Q3 2022 was Great Point Partners, an estimated $5.16M added.
- The largest Generation Bio seller in Q3 2022 was Yiheng Capital Management, an estimated $10M sold.
Based on aggregated 13F filings for Q3 2022.